Isabel Almeida

Isabel Almeida

Auto-generated profile, based on publicly available information

Isabel Almeida

Internal Medicine, UIC-Unidade de Imunologia Clínica, Centro Hospitalar Universitário do Porto, Member of European Reference Network RITA and ReCONNECT, Responsible of the UIC Systemic Sclerosis Cohort, UMIB, ICBAS, Universidade do Porto, Portugal

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Autoimmunity Reviews
Verified
Journal Article
Closed access
CACristiana Almeida
Cristiana Almeida
IAIsabel Almeida
Isabel Almeida
CVCarlos Vasconcelos
Carlos Vasconcelos

29 October 2015 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ABAndreia Bettencourt
Andreia Bettencourt
CCCláudia Carvalho
Cláudia Carvalho
BLBárbara Leal
Bárbara Leal
SBSandra Brás
Sandra Brás
DLDina Lopes
Dina Lopes
BSBerta Martins da Silva
Berta Martins da Silva
Autoimmune diseases (AIDs) are characterized by a multifactorial aetiology and a complex genetic background, with the MHC region playing a major role. We genotyped for HLA-DRB1 locus 1228 patients with AIDs-213 with Systemic Lupus Erythematosus (SLE), 166 with Psoriasis or Psoriatic Arthritis (Ps + PsA), 153 with Rheumatoid Arthritis (RA), 67 with Systemic Sclerosis (SSc), 536 with Multiple Sclerosis (MS), and 93 with Myasthenia Gravis (MG) and 282 unrelated controls. We confirmed previously established associations of HLA-DRB115 (OR = 2.17) and HLA-DRB103 (OR = 1.81) alleles with MS, HLA-DRB103 with SLE (OR = 2.49), HLA-DRB101 (OR = 1.79) and HLA-DRB104 (OR = 2.81) with RA, HLA-DRB107 with Ps + PsA (OR = 1.79), HLA-DRB101 (OR = 2.28) and HLA-DRB108 (OR = 3.01) with SSc, and HLA-DRB103 with MG (OR = 2.98). We further observed a consistent negative association of HLA-DRB113 allele with SLE, Ps + PsA, RA, and SSc (18.3%, 19.3%, 16.3%, and 11.9%, resp., versus 29.8% in controls). HLA-DRB113 frequency in the AIDs group was 20.0% (OR = 0.58). Although different alleles were associated with particular AIDs, the same allele, HLA-DRB113, was underrepresented in all of the six diseases analysed. This observation suggests that this allele may confer protection for AIDs, particularly for systemic and rheumatic disease. The protective effect of HLA-DRB113 could be explained by a more proficient antigen presentation by these molecules, favouring efficient clonal deletion during thymic selection.

6 February 2015 in Lupus
Verified
Journal Article
Closed access
PDF file
CCC Carvalho
C Carvalho
AMAntonio Marinho
Antonio Marinho
BLBárbara Leal
Bárbara Leal
ABA Bettencourt
A Bettencourt
DBD Boleixa
D Boleixa
BSB M Silva
B M Silva
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown origin, in which both genetic and environmental factors are involved. One such environmental factor is vitamin D, a vital hormone that plays a specific function in the immune system homeostasis, acting through a nuclear receptor (VDR) expressed in all immune cells. Several polymorphisms of the gene that encodes this receptor have been described. Though inconsistently, these polymorphisms have been associated with clinical manifestations and SLE development. The aim of this study was to determine the possible association between VDR gene polymorphisms (BsmI, ApaI, TaqI e FokI) and SLE susceptibility and severity, in a cohort of lupus patients from the north of Portugal. A total of 170 patients (F = 155, M = 15; age = 45 ± 13.4 years) with SLE (diagnosed according the American College of Rheumatology criteria) with at least five years of disease evolution and followed in the Autoimmune Disease Clinical Immunology Unit of Centro Hospitalar do Porto were studied. Patients and 192 ethnicity-matched controls were genotyped for BsmI (rs1544410), ApaI (rs7975232), TaqI (rs731236) and FokI (rs2228570) polymorphisms by TaqMan allelic discrimination assay. Disease severity was assessed by SLICC damage score, number of affected organs, number of severe flares and pharmacological history. SLE patients with the CT genotype of FokI polymorphism have a higher SLICC value (p = 0.031). The same result was observed for the group of patients with the TT genotype of TaqI polymorphism (p = 0.046). No differences were observed in VDR genotype between patients and controls. Also, we observed that the other clinical features analysed were not influenced by VDR polymorphisms. Our study confirms a possible role of VDR gene polymorphisms in SLE. A positive association was found between VDR polymorphisms and SLE severity (chronic damage). The presence of CT genotype of FokI and TT genotype of TaqI seems to confer a worse prognosis and may constitute a risk factor for higher long-term cumulative damage in SLE patients.

18 September 2015 in Lupus
Verified
Journal Article
Open access
CAC Andrade
C Andrade
TMT Mendonça
T Mendonça
FFF Farinha
F Farinha
JCJ Correia
J Correia
AMAntonio Marinho
Antonio Marinho
CVC Vasconcelos
C Vasconcelos
Diffuse alveolar hemorrhage (DAH) is a rare but potentially catastrophic manifestation with a high mortality. Among rheumatologic diseases, it occurs most frequently in patients with systemic lupus erythematosus (SLE) and systemic vasculitis. Despite new diagnostic tools and therapies, it remains a diagnostic and therapeutic challenge. The aim of this work was to characterize the SLE patients with an episode of alveolar hemorrhage followed in our Clinical Immunology Unit (CIU). A retrospective chart review was carried out for all patients with SLE followed in CIU between 1984 and the end of 2013. We reviewed the following data: demographic characteristics, clinical and laboratory data, radiologic investigations, histologic studies, treatment, and outcome. We identified 10 episodes of DAH, corresponding to seven patients, all female. These represent 1.6% of SLE patients followed in our Unit. The age at DAH attack was 42.75 ± 18.9 years. The average time between diagnosis of SLE and the onset of DAH was 7.1 years. Three patients had the diagnosis of SLE and the DAH attack at the same time. Disease activity according to SLEDAI was high, ranging from 15 to 41. All patients were treated with methylprednisolone, 37.5% cyclophosphamide and 28.6% plasmapheresis. The overall mortality rate was 28.6%.

15 July 2009 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
GCGraziela Carvalheiras
Graziela Carvalheiras
PVPedro Vita
Pedro Vita
SMSusana Marta
Susana Marta
RTRita Trovão
Rita Trovão
FFFátima Farinha
Fátima Farinha
CVCarlos Vasconcelos
Carlos Vasconcelos

7 October 2015 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
IAIsabel Almeida
Isabel Almeida
SSSara Vieira Silva
Sara Vieira Silva
AFAna Raquel Fonseca
Ana Raquel Fonseca
ISIVONE SILVA
IVONE SILVA
CVCarlos Vasconcelos
Carlos Vasconcelos
MLMargarida Lima
Margarida Lima